JMP Securities Forecasts Strong Price Appreciation for DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies (NASDAQ:DBVT) had its price objective increased by stock analysts at JMP Securities from $15.00 to $21.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ price objective suggests a potential upside of 124.60% from the company’s previous close.

A number of other research analysts also recently issued reports on DBVT. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, May 9th. HC Wainwright raised their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, May 5th.

DBV Technologies Price Performance

NASDAQ DBVT opened at $9.35 on Tuesday. The firm’s fifty day moving average price is $8.27 and its 200 day moving average price is $5.41. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $12.78. The company has a market capitalization of $256.10 million, a price-to-earnings ratio of -2.08 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, sell-side analysts forecast that DBV Technologies will post -7.05 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.